Literature DB >> 2831811

LY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococci.

A S Bayer1, J Yih, L Hirano.   

Abstract

Rabbits with group G streptococcal aortic endocarditis received no therapy (controls); repeated doses of procaine penicillin G, 300 mg/kg (body weight) per day, administered intramuscularly; or LY146032, a new peptolide antibiotic, 20 mg/kg per day, administered intravenously. Penicillin G and LY146032 reduced mean intravegetation group G streptococcal densities significantly below those observed in controls at both day 3 and day 6 of therapy. Penicillin G effected a more rapid clearance of intravegetation streptococci than LY146032 by day 3, but not by day 6, of therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2831811      PMCID: PMC172116          DOI: 10.1128/AAC.32.1.141

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

2.  Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits.

Authors:  D T Durack; P B Beeson; R G Petersdorf
Journal:  Br J Exp Pathol       Date:  1973-04

3.  Group G streptococcal arthritis.

Authors:  M M Nakata; J H Silvers; W L George
Journal:  Arch Intern Med       Date:  1983-07

4.  Septic arthritis due to group G streptococcus.

Authors:  N K Fujita; K Lam; A S Bayer
Journal:  JAMA       Date:  1982-02-12       Impact factor: 56.272

5.  Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.

Authors:  M A Sande; M L Johnson
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

6.  Experimental endocarditis due to Pseudomonas aeruginosa. I. Description of a model.

Authors:  G Archer; F R Fekety
Journal:  J Infect Dis       Date:  1976-07       Impact factor: 5.226

7.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

8.  Therapy of experimental Pseudomonas endocarditis with high-dose amikacin and ticarcillin.

Authors:  C Choi; A S Bayer; N K Fujita; K Lam; L B Guze; T T Yoshikawa
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

9.  Serious infections due to group G streptoccocci. Report of 15 cases with in vitro-in vivo correlations.

Authors:  K Lam; A S Bayer
Journal:  Am J Med       Date:  1983-10       Impact factor: 4.965

10.  Comparison of a micromethod for performance of the serum bactericidal test with the standard tube dilution method.

Authors:  C G Prober; S S Dougherty; K L Vosti; A S Yeager
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

View more
  4 in total

1.  Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.

Authors:  M C Ramos; M L Grayson; G M Eliopoulos; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.

Authors:  L Cantoni; M P Glauser; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; V N Reddy; E M Bailey; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.